omeros.com (OMER): Forward P/E Multiple

Graphic logo of omeros.com (OMER)

Omeros Corporation (OMER) is developing innovative treatments for nervous system pathologies. The firm's prospects rely on the approval of new therapies and the success of core drugs, including their adoption by physicians. Revenues are based on a niche market for targeted care for rare disorders, where hematology centers are showing interest in the products. Market price action with the 15.90 metric illustrates the current valuation of the business.

Future Price to Earnings Multiple: omeros.com (OMER) for 07/04/2022 - 11/17/2026

Analytical breakdowns and data insights for company Omeros (OMER)

- stock value and consensus price forecast:
Fundamental valuation:Omeros Corporation
Signature product of omeros.com

Omeros Corporation's strong patent barriers in the field of MASP-2 inhibitors drive the investment attractiveness reflected in the forward P/E. This metric compares the current share price with the expected earnings per share. By analyzing the forward P/E multiple for the company, an investor can see the current value of 15.90 relative to market norms. This allows for an assessment of the premium paid for future FDA successes. A low ratio confirms the fundamental resilience of the business.

Competitors of Omeros Corporation

Forward P/E Multiple BIIB|NBIX - Projected Price to Earnings Ratio|Forward P/E Multiple RGC (Regencell Bioscience Ltd)|Market Cap to Projected Earnings axsome.com (AXSM)|ACADIA Pharmaceuticals Inc - Forward P/E Multiple|Projected Price to Earnings Ratio Xenon Pharmaceuticals Inc.|Viking Therapeutics (VKTX) - Future Price to Earnings|Supernus Corp - Future Price to Earnings Multiple|Projected Price to Earnings CPRX|Denali Therapeutics Inc. (DNLI) - Market Cap to Projected Earnings|Projected Price to Earnings HRMY (Harmony Corp)|BHVN - Projected Price to Earnings Ratio|Future Price to Earnings Amylyx Pharmaceuticals, Inc. AMLX|Future Price to Earnings Multiple TRVI|PRAX - Future Price to Earnings|Market Cap to Projected Earnings Anavex Life Sciences AVXL|CBLL: Forward P/E Multiple|Projected Price to Earnings Prothena Corporation PLC|ALEC (alector.com) - Forward P/E Multiple|Projected Price to Earnings Annexon, Inc. (ANNX)|Future Price to Earnings Neurogene (NGNE)|Market Cap to Projected Earnings AC Immune SA|Forward P/E Multiple VYGR (voyagertherapeutics.com)|Forward P/E Multiple Neumora NMRA|Scilex Holding - Forward P/E Multiple|Projected Price to Earnings Ratio Tevogen Bio Inc.|Alpha Cognition (ACOG) - Future Price to Earnings|cogrx.com (CGTX) - Forward P/E Multiple|Future Price to Earnings Inhibikase Therapeutics|Cassava (SAVA) - Market Cap to Projected Earnings|Future Price to Earnings Assertio Therapeutics (ASRT)|Market Cap to Projected Earnings Coya|Vistagen - Projected Price to Earnings|Future Price to Earnings Multiple OVID|Acumen Pharmaceuticals Inc. - Forward P/E Multiple|Projected Price to Earnings Ratio CervoMed Inc|ATHE: Forward P/E Multiple|Projected Price to Earnings Clene Nanomedicine|Future Price to Earnings PepGen Corp|Jupiter Neurosciences (JUNS) - Market Cap to Projected Earnings|Future Price to Earnings Relmada Therapeutics, Inc. (RLMD)|ANVS - Projected Price to Earnings Ratio|gracetx.com - Projected Price to Earnings|AIFF: Price to Future Earnings Ratio|Klotho Neurosciences - Forward P/E Multiple|NRSN (NeuroSense Therapeutics Ltd.) - Price to Future Earnings Ratio|Reviva Pharmaceuticals (RVPH) - Future Price to Earnings|MTVA (MetaVia Inc.) - Future Price to Earnings|Future Price to Earnings NeurAxis, Inc|Future Price to Earnings HSDT|Forward P/E Multiple PASG|Market Cap to Projected Earnings Neuphoria Therapeutics, Inc.|minervaneurosciences.com - Projected Price to Earnings|Forward P/E Multiple Athira ATHA|Addex Therapeutics - Forward P/E Multiple|ALZN - Forward P/E Multiple|Cyclerion (CYCN) - Future Price to Earnings|Protagenic (PTIX) - Forward P/E Multiple|Future Price to Earnings Pasithea|Price to Future Earnings Ratio CRGT (Cortigent)|Future Price to Earnings Avenue Therapeutics (ATXI)|BCLI - Projected Price to Earnings Ratio|Forward P/E Multiple CARA (Cara Therapeutics Inc)|CHRO - Projected Price to Earnings|ELYM: Projected Price to Earnings|Market Cap to Projected Earnings Intra-Cellular Therapies, Inc. ITCI|Longboard Pharma (LBPH) - Future Price to Earnings|Marinus - Future Price to Earnings Multiple|Future Price to Earnings NKGen Biotech Inc|NRBO: Future Price to Earnings Multiple|Projected Price to Earnings SAGE (Sage Therapeutics, Inc.)|Market Cap to Projected Earnings Neurotrope|Future Price to Earnings Trevena, Inc. TRVN|Vigil Neuroscience (VIGL) - Projected Price to Earnings Ratio|WENA: Projected Price to Earnings|Future Price to Earnings Multiple CERE (Cerevel Therapeutics)